2. Disease Areas
  3. Inflammation or Immune System Disease
  4. Pathogens Infection
  5. Sepsis

Sepsis

Bacterial sepsis is a life-threatening condition resulting from the body's extreme response to a bacterial infection, leading to systemic inflammation and potential organ dysfunction. It arises when bacteria enter the bloodstream, triggering a dysregulated immune response that can progress to septic shock and death if not promptly treated. Common symptoms include fever, rapid heart rate, fast breathing, confusion, and severe body pain, with advanced cases showing signs of organ failure. In premature infants, sepsis is a rare but critical illness characterized by systemic organ dysfunction due to infection acquired before or during birth—classified as early-onset or late-onset neonatal sepsis. Risk factors include prematurity, and clinical manifestations range from nonspecific signs like irritability and poor feeding to severe complications such as respiratory distress, hypotension, shock, and multi-organ failure. Early recognition and aggressive treatment are essential for survival.

References:

Sepsis (7):

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-18257
    Rolitetracycline 751-97-3 ≥98.0%
    Rolitetracycline is a highly soluble, broad-spectrum antibiotic derived from tetracycline. Rolitetracycline binds to and stabilizes bovine serum albumin, and also inhibits HIV-1 integrase, blocks Aβ fibril formation and suppresses dengue virus proliferation. Rolitetracycline mediates the inhibition of Aβ fibrils via a specific three-dimensional pharmacophore conformation, and exerts bacteriostatic and bactericidal activities. Rolitetracycline acts synergistically with Penicillin G (HY-N7139) or Cephalothin (HY-B1275A) to alter the effects on microbial growth. Rolitetracycline serves as an important tool compound for the study of bacterial infections (urinary tract infections, sepsis), HIV-1 and dengue virus infections, as well as Alzheimer's disease.
    Rolitetracycline
  • HY-P2936A
    Sphingomyelin phosphodiesterase, Bacillus cereus 9031-54-3
    Sphingomyelin phosphodiesterase, Bacillus cereus is a sphingomyelin hydrolase and Insecticide. Sphingomyelin phosphodiesterase, Bacillus cereus catalyzes the decomposition of sphingomyelin into ceramide and phosphorylcholine. Sphingomyelin phosphodiesterase, Bacillus cereus causes rapid paralysis and death in injected insects, including German cockroaches and black cutworms. Sphingomyelin phosphodiesterase, Bacillus cereus reduces H2O2 production. Sphingomyelin phosphodiesterase, Bacillus cereus can be used in studies related to sepsis and endophthalmitis.
    Sphingomyelin phosphodiesterase, Bacillus cereus
  • HY-182409
    TSI-13-48 2254006-84-1
    TSI-13-48 (HY-182409) is a TLR inhibitor with IC50 values of 3.02, 22.3, 26.5, and 26.6 μM against TLR9, TLR7, TLR2, and TLR4, respectively. TSI-13-48 can be used in research related to systemic lupus erythematosus, polymicrobial sepsis, and cerebral malaria.
    TSI-13-48
  • HY-182377
    DT-5461 123598-19-6
    DT-5461 is an IL-1 and TNF-α antagonist. DT-5461 competitively binds lipid A-binding sites on macrophage receptors, blocks LPS (HY-D1056)-initiated signaling, inhibits LPS-induced cytokine release, prevents LPS-induced serum cytokine production in mice, and protects against LPS-induced lethal endotoxemia. DT-5461 can be used for the research of lethal endotoxemia, medullary tubular mammary carcinoma, poorly differentiated colon adenocarcinoma, squamous-cell lung carcinoma, and gelatinous gastric adenocarcinoma.
    DT-5461
  • HY-181168
    Lb54
    Lb54 is a caspase-3 and caspase-7 activator with an EC50 of 660.9 nM for human procaspase-3. Lb54 activates caspase-3/7, which cleaves Gasdermin D (GSDMD) at aspartic acid residue 87 to generate a p10 fragment, preventing formation of the pore-forming p30 fragment of GSDMD. Lb54 suppresses GSDMD-mediated pyroptosis through caspase-3/7 activation, thereby attenuating inflammatory responses and conferring protection against sepsis. Lb54 alleviates acute lung injury, and inhibited systemic inflammation by restraining the maturation of monocyte-derived dendritic cells. Lb54 can be used for the research of sepsis.
    Lb54
  • HY-B0368B
    D-Captopril 119238-52-7
    D-Captopril is a NDM-1 inhibitor and a competitive BlaB inhibitor, with an IC50 value of 21.8 µM against NDM-1 and a Ki of 70-100 µM against BlaB. D-Captopril synergistically reduces the minimum inhibitory concentration of Meropenem (HY-13678) against NDM-1-expressing bacteria. D-Captopril binds to BcII via its thiolate sulfur atom and carboxylate group, altering metal ion occupancy and modulating Cd2+ binding affinity. D-Captopril can be used in the research of neonatal meningitis, sepsis and bacterial infections.
    D-Captopril
  • HY-130581
    Lipid X 86559-73-1
    Lipid X is a 2,3-diacylglucosamine-1-phosphate that serves as the monosaccharide precursor of lipid A, possessing both LPS antagonist and weak agonist activities. Lipid X exerts protective effects by inhibiting tumor necrosis factor production, monocyte procoagulant activity, and neutrophil priming. Lipid X may induce transient pulmonary hypertension, neutropenia, and mild pyrogenic effects in laboratory animals. Lipid X has low toxicity and no in vitro antibacterial activity, but it significantly reduces mortality following Gram-negative bacterial infection and endotoxin exposure. Lipid X tends to accumulate in liver tissue, binds to circulating cellular components, and can be converted to lipid Y through transesterification. Lipid X can be used in research on Gram-negative bacterial sepsis, endotoxemia, and associated pulmonary hypertension.
    Lipid X